LYKA LABS Financial Statement Analysis
|
||
|
The Revenues of LYKA LABS have decreased by -52.05% YoY .
The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LYKA LABS Last 5 Annual Financial Results
[BOM: 500259|NSE : LYKALABS]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹93 Cr | ₹194 Cr | ₹86 Cr | ₹61 Cr | ₹71 Cr |
| Expenses | ₹76 Cr | ₹93 Cr | ₹67 Cr | ₹65 Cr | ₹73 Cr |
| Operating Profit (Excl OI) | ₹17 Cr | ₹101 Cr | ₹20 Cr | ₹-3.67 Cr | ₹-1.90 Cr |
| Other Income | ₹3.40 Cr | ₹2.09 Cr | ₹1.56 Cr | ₹3.09 Cr | ₹2.09 Cr |
| Interest | ₹12 Cr | ₹20 Cr | ₹26 Cr | ₹20 Cr | ₹7.17 Cr |
| Depreciation | ₹14 Cr | ₹17 Cr | ₹8.32 Cr | ₹8.01 Cr | ₹7.31 Cr |
| Profit Before Tax | ₹-13 Cr | ₹59 Cr | ₹-14 Cr | ₹-62 Cr | ₹-15 Cr |
| Profit After Tax | ₹-13 Cr | ₹38 Cr | ₹-10 Cr | ₹-63 Cr | ₹-6.35 Cr |
| Consolidated Net Profit | ₹-13 Cr | ₹39 Cr | ₹-12 Cr | ₹-61 Cr | ₹-5.55 Cr |
| Earnings Per Share (Rs) | ₹-0.75 | ₹-4.30 | ₹13.59 | ₹-4.03 | ₹-21.10 |
| PAT Margin (%) | -2.36 | -14.13 | 19.81 | -11.70 | -101.84 |
| ROE(%) | -6.02 | -63.63 | 0.00 | 0.00 | -448.65 |
| ROCE(%) | 3.26 | -1.00 | 56.68 | 8.95 | -31.39 |
| Total Debt/Equity(x) | 0.96 | 2.58 | 9.76 | -6.30 | -9.85 |
Key Financials |
||
| Market Cap | : | ₹ 534.3 Cr |
| Revenue (TTM) | : | ₹ 131.6 Cr |
| Net Profit(TTM) | : | ₹ 3.1 Cr |
| EPS (TTM) | : | ₹ 0.9 |
| P/E (TTM) | : | 170.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LYKA LABS | -7.3% | 6.3% | 27.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
| CIPLA | 1.7% | 0.5% | 23.7% |
| DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
| ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
| DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
| MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
| TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
| LUPIN | 4.1% | 5.1% | 71.7% |
LYKA LABS Revenues
[BOM: 500259|NSE : LYKALABS]
| Y-o-Y | -52.05 % |
| 5 Yr CAGR | 7.08 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹93 Cr | -52.05 | |
| Mar2023 | ₹194 Cr | 125.02 | |
| Mar2022 | ₹86 Cr | 40.27 | |
| Mar2021 | ₹61 Cr | -13.13 | |
| Mar2020 | ₹71 Cr | - | |
LYKA LABS Operating Profit
[BOM: 500259|NSE : LYKALABS]
| Y-o-Y | -83.35 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹17 Cr | -83.35 | |
| Mar2023 | ₹101 Cr | 413.90 | |
| Mar2022 | ₹20 Cr | Positive | |
| Mar2021 | ₹-3.67 Cr | Negative | |
| Mar2020 | ₹-1.90 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -65.29 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 18.09% | -65.29 | |
| Mar2023 | 52.12% | 128.40 | |
| Mar2022 | 22.82% | Positive | |
| Mar2021 | -5.97% | Negative | |
| Mar2020 | -2.68% | - | |
LYKA LABS Profit After Tax
[BOM: 500259|NSE : LYKALABS]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹-13 Cr | Negative | |
| Mar2023 | ₹39 Cr | Positive | |
| Mar2022 | ₹-12 Cr | Negative | |
| Mar2021 | ₹-61 Cr | Negative | |
| Mar2020 | ₹-5.55 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | -2.36 % | Negative | |
| Mar2023 | -14.13 % | Negative | |
| Mar2022 | 19.81 % | Positive | |
| Mar2021 | -11.7 % | Negative | |
| Mar2020 | -101.84 % | - | |
LYKA LABS Earnings Per Share (EPS)
[BOM: 500259|NSE : LYKALABS]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹-0.75 | Negative | |
| Mar2023 | ₹-4.30 | Negative | |
| Mar2022 | ₹14 | Positive | |
| Mar2021 | ₹-4.03 | Negative | |
| Mar2020 | ₹-21 | - | |
LYKA LABS Return on Capital Employed (ROCE)
[BOM: 500259|NSE : LYKALABS]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 3.26% | Positive | |
| Mar2023 | -1% | Negative | |
| Mar2022 | 56.68% | 533.30 | |
| Mar2021 | 8.95% | Positive | |
| Mar2020 | -31.39% | - | |
LYKA LABS Share Price vs Sensex
| Current Share Price | : | ₹149.7 |
| Current MarketCap | : | ₹ 534.3 Cr |
| Updated EOD on | : | Dec 20,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LYKA LABS | -7.3% |
6.3% |
27.8% |
| SENSEX | -5% |
0.6% |
9.2% |
LYKA LABS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about LYKA LABS Financials
How the annual revenues of LYKA LABS have changed ?
The Revenues of LYKA LABS have decreased by -52.05% YoY .
How the Earnings per Share (EPS) of LYKA LABS have changed?
The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY .
Check out Intrinsic Value of Peers of LYKA LABS
Compare Stock Analytics of Peers of LYKA LABS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
